Health Economics And Radium-223 (Xofigo®) In The Treatment Of Metastatic Castration-Resistant Prostate Cancer (Mcrpc). A Case History And A Systematic Review Of The Literature On Cost-Effectiveness Analysis (Cea)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1191
https://www.valueinhealthjournal.com/article/S1098-3015(15)03267-2/fulltext
Title :
Health Economics And Radium-223 (Xofigo®) In The Treatment Of Metastatic Castration-Resistant Prostate Cancer (Mcrpc). A Case History And A Systematic Review Of The Literature On Cost-Effectiveness Analysis (Cea)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03267-2&doi=10.1016/j.jval.2015.09.1191
First page :
A460
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
690